Vaxcyte said its pivotal Phase III study of VAX-31 in adults met all endpoints. It plans a BLA filing in the first half of 2028, with two more Phase III studies reading out in the first half of next year. Infant Phase II data for VAX-31 is also expected in the first half of next year.
PCVX · Vaxcyte, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
VaxCite said its adult Vax31 Phase III data exceeded expectations, while the program remains on track for a BLA submission in the first half of 2028.
VAX-31 met all prespecified primary endpoints in the pivotal adult Phase 3 OPUS-1 trial and was well tolerated. Vaxcyte raised approximately $1.15 billion in October 2026 and held $2.3 billion of cash, cash equivalents and investments as of September 30, 2026.
Vaxcyte reported that VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial. Third-quarter net loss was $297.1 million, while cash, cash equivalents and investments totaled $2,264.4 million as of September 30, 2026.
On October 9, 2026, Vaxcyte closed a $575,000,000 1.50% convertible senior notes offering due 2032 and an equity offering, generating approximately $558.7 million and $544.3 million in net proceeds, respectively.
Metrics snapshot
Useful current figures from the complete screener profile.
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCVX
this stock
Vaxcyte, Inc.
|
$9.26B | +26.8% | — | — | 9.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 23
Vaxcyte said its pivotal Phase III study of VAX-31 in adults met all endpoints. It plans a BLA filing in the first half of 2028, with two more Phase III studies reading out in the first half of next year. Infant Phase II data for VAX-31 is also expected in the first half of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCVX | -14.7% | -7.5% | +13.9% | -5.7% | +26.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -10.8% | -1.9% | +17.3% | -2.3% | +19.8% |